In Brief: Abbott's Ritonavir
Abbott's Ritonavir: FDA Antiviral Drugs Advisory Committee will meet Feb. 29 to consider Abbott's NDA for the protease inhibitor for treatment of HIV infection. On. Feb. 28, the committee will discuss data from AIDS Clinical Trial Group study 175 and other studies with Bristol-Myers Squibb's Videx, Glaxo Welcome's Retrovir and Roche's Hivid. The committee will meet jointly with FDA's Endocrinologic & Metabolic Drugs Advisory Committee on March 1 to discuss Serono's NDA for Serostim hgH for AIDS wasting syndrome. The three-day meeting will be held at the Holiday Inn in Gaithersburg, Md. starting at 8:30 a.m. on Feb. 28 & 29, and at 8 a.m. March 1...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth